Nivestym is a Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Filgrastim.
| Product ID | 0069-0294_3a976868-6b9c-44b2-987a-3ec9cda3e7a1 |
| NDC | 0069-0294 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Nivestym |
| Generic Name | Filgrastim-aafi |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVENOUS; SUBCUTANEOUS |
| Marketing Start Date | 2019-03-11 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761080 |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Substance Name | FILGRASTIM |
| Active Ingredient Strength | 480 ug/1.6mL |
| Pharm Classes | Granulocyte Colony-Stimulating Factor [CS], Granulocyte-Macrophage Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2019-03-11 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA761080 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2019-03-11 |
| Marketing Category | BLA |
| Application Number | BLA761080 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2019-03-11 |
| Ingredient | Strength |
|---|---|
| FILGRASTIM | 480 ug/1.6mL |
| SPL SET ID: | d23ab39c-b6ec-41cf-a529-9dd2852c9d9a |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0069-0291 | Nivestym | filgrastim-aafi |
| 0069-0292 | Nivestym | filgrastim-aafi |
| 0069-0293 | Nivestym | filgrastim-aafi |
| 0069-0294 | Nivestym | filgrastim-aafi |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() NIVESTYM 86914849 5722625 Live/Registered |
Hospira, Inc. 2016-02-22 |